Skip to main content

Research Repository

Advanced Search

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

Abdel-Fatah, T.M.A.; McArdle, S.E.B.; Johnson, C.; Moseley, P.M.; Ball, G.R.; Pockley, A.G.; Ellis, I.O.; Rees, R.C.; Chan, S.Y.T.

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer Thumbnail


Authors

T.M.A. Abdel-Fatah

S.E.B. McArdle

C. Johnson

P.M. Moseley

G.R. Ball

A.G. Pockley

R.C. Rees

S.Y.T. Chan



Abstract

Background: HAGE protein is a known immunogenic cancer-specific antigen.
Methods: The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n ¼ 2147): early primary (EP-BC; n ¼ 1676); primary oestrogen receptor-negative (PER-BC; n ¼ 275) treated with adjuvant anthracycline-combination therapies (Adjuvant-ACT); and primary locally advanced disease (PLA-BC) who received neo-adjuvant anthracycline-combination therapies (Neo-adjuvant-ACT; n ¼ 196). The relationship between HAGE expression and the tumour-infiltrating lymphocytes (TILs) in matched prechemotherapy and postchemotherapy samples were investigated.
Results: Eight percent of patients with EP-BC exhibited high HAGE expression (HAGE þ ) and was associated with aggressive
clinico-pathological features (Pso0.01). Furthermore, HAGE þ expression was associated with poor prognosis in both univariate and multivariate analysis (Pso0.001). Patients with HAGE þ did not benefit from hormonal therapy in high-risk ER-positive disease. HAGE þ and TILs were found to be independent predictors for pathological complete response to neoadjuvant-ACT; Po0.001. A statistically significant loss of HAGE expression following neoadjuvant-ACT was found (P ¼ 0.000001), and progression-free survival was worse in those patients who had HAGE þ residual disease (P ¼ 0.0003).
Conclusions: This is the first report to show HAGE to be a potential prognostic marker and a predictor of response to ACT in patients with BC.

Citation

Abdel-Fatah, T., McArdle, S., Johnson, C., Moseley, P., Ball, G., Pockley, A., …Chan, S. (2014). HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. British Journal of Cancer, 110(10), 2450-2461. https://doi.org/10.1038/bjc.2014.168

Journal Article Type Article
Acceptance Date Mar 5, 2014
Online Publication Date Apr 22, 2014
Publication Date 2014-05
Deposit Date Dec 5, 2018
Publicly Available Date Apr 9, 2019
Journal British Journal of Cancer
Print ISSN 0007-0920
Electronic ISSN 1532-1827
Publisher Cancer Research UK
Peer Reviewed Peer Reviewed
Volume 110
Issue 10
Pages 2450-2461
DOI https://doi.org/10.1038/bjc.2014.168
Public URL https://nottingham-repository.worktribe.com/output/1371112
Publisher URL https://www.nature.com/articles/bjc2014168

Files




You might also like



Downloadable Citations